CagriSema FDA Decision: What Approval or a CRL Would Change

One FDA action in the fourth quarter of 2026 will decide whether the first GLP-1/amylin combination reaches the US market — and, just as importantly, what its label is allowed to say. CagriSema is the most consequential pending decision in obesity medicine, and it arrives carrying an awkward fact: in its own head-to-head trial, it lost to tirzepatide.

What the FDA Is Actually Reviewing

The application is a fixed-dose combination of two established mechanisms: cagrilintide 2.4 mg, a long-acting amylin and calcitonin receptor agonist, and semaglutide 2.4 mg, the GLP-1 agonist in Wegovy. Both are given once weekly in a single device.

The efficacy case comes from two 68-week trials. REDEFINE 1 enrolled 3,417 adults with obesity or overweight without diabetes and produced 20.4% weight loss against 14.9% for semaglutide alone, 11.5% for cagrilintide alone and 3.0% for placebo. REDEFINE 2 enrolled 1,206 adults with obesity and type 2 diabetes, a population where every incretin underperforms, and produced 13.7% against 3.1% for placebo.

Those are strong, registrational numbers. They are also the numbers the FDA will weigh against a safety profile dominated by gastrointestinal events, and against a manufacturing change: Novo abandoned its single-chamber device for CagriSema, a decision the company insists does not alter its launch plan.

The Trial That Complicates the Story

REDEFINE 4 was the trial Novo did not have to run and probably wishes it had not. It randomized 809 adults with obesity to open-label CagriSema or tirzepatide 15 mg for 84 weeks, with a primary endpoint of noninferiority.

REDEFINE 1 and 2 figures are the published New England Journal of Medicine results. Some sponsor materials report 22.7% and 15.7% for the same trials using a trial-product estimand; both are correct and answer different questions.

The interpretation matters more than the number. CagriSema did not fail to lose weight; it failed to lose as much as tirzepatide by a margin the trial was designed to exclude. Amylin agonism added roughly 5.5 points on top of semaglutide, and that addition was still not enough to match dual GIP/GLP-1 agonism. Novo's own framing — that cagrilintide adds to GLP-1 biology — is defensible. Its implicit claim that the combination would beat the best available drug is not.

If the FDA Approves

Approval would do four things at once:

• Create a new US drug class. CagriSema would be the first amylin-based obesity therapy on the market, distinct from GLP-1, GIP/GLP-1 and triple agonists.
• Set the label's comparative language. Because REDEFINE 4 missed its endpoint, the label is unlikely to support a superiority claim over tirzepatide. Expect the wording to describe the combination on its own merits rather than against Zepbound.
• Open a Canadian file. Health Canada accepted the CagriSema new drug submission in March 2026. A Canadian authorization would not be expected before 2027, and pricing and reimbursement would follow separately.
• Change nothing about cagrilintide supply. An approval covers Novo's finished combination product only. Research-grade cagrilintide remains unapproved, and the FDA has already sent warning letters to sellers offering it.

If the FDA Declines

A complete response letter would not end the program, but it would reset the clock. The most likely issues in a CagriSema CRL are manufacturing and device-related rather than efficacy-related, given that the efficacy package is already published in a peer-reviewed journal. Novo would need to respond, and a resubmission typically adds six to twelve months.

The strategic damage would be larger than the timeline. Novo has positioned CagriSema as its answer to tirzepatide and as the bridge to zenagamtide. A delay would hand Lilly a full year of uncontested oral and triple-agonist momentum, and would push the amylin-combination story entirely onto Lilly's eloralintide programs.

What to Watch After the Decision

• REDEFINE 11 — the next readout in the program, which Novo has pointed to as evidence of the combination's full potential.
• The higher-dose CagriSema trial — Novo's explicit attempt to close the gap with tirzepatide through dose rather than mechanism.
• Health Canada's decision — the separate Canadian file accepted in March 2026.
• EU and UK filings — CagriSema was not on the EMA's August 2026 list of applications under CHMP evaluation, so a European file has not yet been confirmed.

Related Reading

Explore Our Research Tools

• Calculate volume and concentration parameters with the Peptide Calculator.
• Structure research intervals inside the Protocol Builder.
• Log baseline metrics with the Protocol Tracker Tool.

Sources

• Novo Nordisk. CagriSema demonstrated 23% weight loss in REDEFINE 4; primary endpoint not achieved. February 23, 2026.
• Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025;393(7):635–647.
• Davies MJ, et al. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine. 2025;393(7):648–659.
• Drug Topics. CagriSema did not meet primary endpoint of noninferiority to tirzepatide. February 24, 2026.
• Peptlas. CagriSema FDA status and jurisdiction table. Verified October 16, 2026.
• FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
• ClinicalTrials.gov records NCT05567796 (REDEFINE 1) and NCT05394519 (REDEFINE 2).